SEC Form 4 · accession 0001477932-16-011219
Innovation Pharmaceuticals Inc. · IPIX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Arthur Peter Bertolino
Officer — Pres. & Chief Medical Officer
Period of report
Jun 30, 2016
Accepted (ET)
Jul 7, 2016 · 1:52 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001355250
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 30, 2016 | A | 1,066,667 | $0.00 | A | 1,066,667 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF1 | $1.39 | Jun 30, 2016 | A | 617,839 | A | — | Jun 30, 2026 | Common Stock | 617,839 | 617,839 | D |
Explanation of responses
- F1The restricted stock and stock options vest 50% on June 27, 2017 and 50% on June 27, 2018, or upon the earliest to occur of the following: (i) completion of both a Phase 2b psoriasis study and a Phase 2 oral mucositis study; (ii) the Company's common stock closes above $3.00 per share (as may be adjusted for any stock splits or similar actions); (iii) the commencement of trading of the Company's common stock on a national securities exchange; or (iv) upon a change of control of the Company, as defined in Mr. Bertolino's employment agreement.